N/A N=201 Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification
Healthy Volunteers
Primary: Inter-rater Reliability Using a Masseter Muscle Prominence Scale (MMPS) — 0.728; 0.711 Kendall's W
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=377 BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence
Masseter Muscle Prominence
Primary: Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90 — 2.2; 51.2 percentage of participants — p=<0.0001
Phase 2 N=150 BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
Masseter Muscle Prominence
Primary: Percentage of Participants Who Achieved Masseter Muscle Prominence Scale (MMPS) Grade ≤ 3 at Day 90 as Assessed by the Investigator — 21.7; 90.6; 91.3 percentage of…
Phase 2 N=187 Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy
Masseter Muscle Hypertrophy
Primary: Change From Baseline in Lower Facial Volume Using VECTRA 3D Images — -8.20; -7.41; -6.84; -4.40 cubic centimeter (cm^3) — p=< 0.001
N/A N=5 HIV Posterior Cheek Enlargement
HIV Posterior Cheek Enlargement
Primary: Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A — 21.4 percentage reduction in masseter volume
N/A N=16 Jowl Improvement With Injectable Fillers
Jowls
Primary: Blinded Physician Jawline Rating Scale (JRS) Assessment on Scale of 0 to 4 at Baseline Versus 4 Weeks After Last Injection. — 2.214; 2.071; 1.857; 1.857 score on a scale…
Phase 4 N=58 Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour
Contour
Primary: Percentage of Participants Who Showed ≥ 1-point Jawline Improvement From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS), as Assessed by the…
N/A N=171 Assessing a New Jaw Support Device During Third Molar Extractions
Impacted Third Molar Tooth · Temporomandibular Disorder
Primary: Occurrence of Pain at Follow-up With Wide Opening, or Pain in the Temple, Jaw Joint or Jaw Muscles. — 26; 32; 54; 53 Participants
N/A N=28 Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Randomized Single Blinded Investigational Trial
Temporomandibular Joint Dysfunction Syndrome
Primary: Self Report of Pain — -.86; -2.0; -1.4; -1.3 Scores on pain intensity scale — p=0.17
N/A N=180 Evaluation of Effectiveness and Safety of Radiesse (+) to Improve the Contour of Jawline by Adding Volume to the Jawline
Improvement of Jawline Contour
Primary: Responder Rate According to the Merz Jawline Assessment Scale (MJAS) — 75.6; 8.8 percentage of participants — p=<0.0001
N/A N=224 To Evaluate Effectiveness and Safety of GP0109 for Jawline Definition
Jawline Definition Deficiency
Primary: Percentage of Responders Based on Blinded Evaluators' Live Assessment of the Galderma Jawline Scale (GJS) — 14.3; 85.1 percentage of participants — p=<0.001
N/A N=15 Cryolipolysis for Jawline Contouring
Body Fat Disorder
Primary: Number of Participants With Unanticipated Adverse Device Effects (UADE) — 0 Participants with UADE reported
N/A N=29 Evaluation of the MJGS Following Radiesse (+) Injection Into the Jawline
Volume Loss of the Jawline
Primary: Percentage of Jawlines Achieving Greater Than or Equal to (>=) 1-point Improvement on Merz Jawline Grading Scale (MJGS) at Week 4 — 92.1; 0; 92.1; 0 percentage of…
N/A N=140 Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition
Jawline Definition
Primary: Percentage of Responders Having At Least a 1-Grade Improvement From Baseline on Both Jawlines Concurrently Based on Galderma Jawline Scale (GJS) at Month 3 as Assessed…
Phase 3 N=75 Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles
Pain, Head · Pain Syndrome · Temporomandibular Disorder
Primary: Change in Jaw Pain as Reported by Patient on Visual Analog Scale (VAS) — 58; 54; -19; -14 score on a scale — p=0.80
Phase 2 N=171 BOTOX® for the Treatment of Platysma Prominence
Platysma Prominence
Primary: Percentage of Participants With at Least 1-Grade Improvement at Day 14 as Rated by Investigator Using the Clinician Allergan Platysma Prominence Scale (C-APPS) — 12.0…
Phase 4 N=16 Submental Study (Sequential Treatment Approach)
Body Fat Disorder
Primary: The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When…
N/A N=32 Lifting and Tightening of the Face and Neck Following an Increased Density Treatment
Skin Laxity
Primary: Improvement in Overall Lifting and Tightening of Skin — 48 percentage of participants improved
N/A N=20 Perioral Rejuvenation and Upper Lip Enhancement
Perioral Rejuvenation · Upper Lip Projection
Primary: Nasal Tip Projection — 0.601 ratio
Phase 3 N=206 Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition
Jawline Definition
Primary: Percentage of Participants Who Show ≥ 1-point Jawline Improvement on Both Sides From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS) — 38.0; 69.0…
N/A N=192 A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation
Chin Retrusion
Primary: Percentage of Participants With a ≥ 1-point Improvement (Decrease) on the Allergan Chin Retrusion Scale (ACSR) Score — 56.3; 27.5 percentage of participants — p=0.0019
N/A N=15 Clinical Assessment of Skin Tightening and Contour Change of Submental Tissue Using Bipolar Radiofrequency Microneedling
Skin Laxity
Primary: Percent Change From Baseline of Soft Tissue Surface Area — -0.18; -017 percent change
N/A N=103 Evaluation of the Ulthera™ System for Obtaining Lift and Tightening of the Cheek Tissue
Mild to Moderate Skin Laxity on Cheek · Mild to Moderate Skin Laxity on Upper Neck · Mild to Moderate Subcutaneous Fat on Cheek
Primary: Change in Overall Lifting and Tightening of Treated Tissue on the Lower Face and Submental Regions. — 68.60 percentage of participants improved
N/A N=74 The Effectiveness of a Physiotherapy Technique in Patients With Chronic Myofascial Temporomandibular Disorder
Myofascial Pain Syndrome · Temporomandibular Disorder
Primary: Changes of Perceived Pain Between Three Time Points (Baseline, Post-treatment, and 3 Months Later) and Between Groups (Sham Simulation and Pressure Release Technique)…
Phase 4 N=30 Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance
Ageing
Primary: Evaluate Overall Facial Improvement Assessed Live by the Investigator and Subjects Using the Global Aesthetic Improvement Scale (GAIS) at 12 Weeks Compared to Baseline…
Phase 4 N=20 Injectable Filler for Cheek Flattening
Malar Deficiency
Primary: Blinded Evaluations of First Impression — 7.35 score on a scale
N/A N=28 Geometrical Facial Deformation According to Posture in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: The Amounts of Change of Landmarks Position According to Posture — 1.0; 2.4; 2.9; 5.6 mm
Phase 3 N=360 Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
Moderate or Severe Submental Fullness
Primary: Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response — 58.3; 62.3; 34.5 percentage of participants — p=<0.001
N/A N=14 Fat Reduction in the Submandibular/Submental Area
Body Fat Disorder
Primary: Proportion of Accurately Identified Pre-Treatment Photos by a Panel of Blinded Independent Reviewers — 11 photos